Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MIF | P14174 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.56 |
| ▸ | GLS | O94925 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13499907 | 0.83 | KMT2A (0.61) | ALDH1A1MEN1POLBMIFKMT2A | |
| SCHEMBL1011592 | 0.82 | POLB (0.68) | ALDH1A1MEN1POLBMIFKMT2A | |
| SCHEMBL9156058 | 0.82 | ALDH1A1 (0.60) | ALDH1A1MEN1POLBMIFKMT2A | |
| SCHEMBL6215399 | 0.82 | NPC1 (0.60) | ALDH1A1MEN1POLBMIFKMT2A | |
| SCHEMBL23966723 | 0.81 | ALDH1A1 (0.60) | ALDH1A1MEN1POLBMIFKMT2A | |
| SCHEMBL5345562 | 0.79 | GLS (0.67) | ALDH1A1MEN1POLBMIFKMT2A | |
| SCHEMBL11865969 | 0.78 | HTT (0.60) | ALDH1A1MEN1POLBMIFKMT2A | |
| SCHEMBL17193491 | 0.78 | GLS (0.82) | ALDH1A1MEN1POLBMIFKMT2A | |
| SCHEMBL19651320 | 0.78 | NPC1 (0.62) | ALDH1A1MEN1POLBMIFKMT2A | |
| SCHEMBL895339 | 0.78 | CCNE1 (0.69) | ALDH1A1MEN1POLBMIFKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| EP-1487435-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003077907-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | HPGDS, PTGDR, PTGER1 | ALDH1A1 222/4885MEN1 3899/4885POLB 1254/4885 |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | CCR3, CCR1, CCR9 | ALDH1A1 2840/4885MEN1 2078/4885POLB 4233/4885 |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | HPGDS, PTGDR, PTGER1 | ALDH1A1 222/4885MEN1 3899/4885POLB 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.